Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells 3,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The shares were sold at an average price of $7.67, for a total value of $23,010.00. Following the completion of the transaction, the chief operating officer now directly owns 543,231 shares in the company, valued at $4,166,581.77. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Tina Marriott also recently made the following trade(s):

• On Thursday, March 21st, Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.75, for a total value of $86,000.00.
• On Thursday, February 22nd, Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $14.89, for a total value of $119,120.00.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded up $0.08 during trading hours on Monday, hitting $8.20. The company had a trading volume of 4,100,880 shares, compared to its average volume of 6,464,984. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.54 and a fifty-two week high of $16.75. The business has a fifty day simple moving average of $10.37 and a 200-day simple moving average of $9.15.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The firm had revenue of $10.89 million for the quarter, compared to analyst estimates of $12.37 million. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. boosted its stake in Recursion Pharmaceuticals by 81.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 43,656 shares of the company’s stock valued at $435,000 after buying an additional 19,565 shares in the last quarter. Cherry Creek Investment Advisors Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 222.4% during the first quarter. Cherry Creek Investment Advisors Inc. now owns 57,556 shares of the company’s stock valued at $574,000 after purchasing an additional 39,703 shares during the last quarter. Wesbanco Bank Inc. purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth about $650,000. Wealth Effects LLC purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth about $150,000. Finally, Azzad Asset Management Inc. ADV purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $161,000. Institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. TD Cowen assumed coverage on Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a “market perform” rating on the stock. Finally, KeyCorp upped their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $12.75.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.